{"id":"nebivolol-neb","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Fatigue"},{"rate":"3-8","effect":"Dizziness"},{"rate":"3-7","effect":"Headache"},{"rate":"2-5","effect":"Bradycardia"},{"rate":"1-3","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL434394","moleculeType":"Small molecule","molecularWeight":"405.44"},"_dailymed":{"setId":"6e43a4e2-574e-4f4a-804d-e346b4edd2f1","title":"NEBIVOLOL TABLET [AUROBINDO PHARMA LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nebivolol blocks beta-1 adrenergic receptors on the heart, reducing heart rate and contractility to lower blood pressure and cardiac workload. Unlike traditional beta-blockers, it also possesses vasodilatory properties mediated by nitric oxide release in endothelial cells, providing additional cardiovascular benefits. This dual mechanism makes it particularly useful in hypertension management with improved tolerability.","oneSentence":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:43.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT06104423","phase":"PHASE4","title":"Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2023-10-02","conditions":"Hypertension","enrollment":266},{"nctId":"NCT00142584","phase":"PHASE3","title":"Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2005-08","conditions":"Hypertension","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nebivolol (NEB)","genericName":"Nebivolol (NEB)","companyName":"Mylan Bertek Pharmaceuticals","companyId":"mylan-bertek-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release. Used for Hypertension, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}